PARP1 and breast carcinoma: In breast cancer cells, the combination of the ATR inhibitor VE-821 and PARP inhibitors synergize to promote cell death independent of HR-proficiency [58], and ATR inhibition via VE-821 overcomes PARP inhibitor resistance in BRCA-deficient cells by disrupting rewired HR and fork protection pathways [59].